8-K: Philip Morris International Reaffirms 2024 Earnings Forecast at Barclays Conference

Philip Morris International reaffirmed its full-year 2024 earnings forecast, projecting a currency-neutral growth of 11% to 13% in adjusted diluted EPS.

Summary

• Philip Morris International (PMI) participated in the 2024 Barclays Global Consumer Staples Conference.
• The company reaffirmed its full-year 2024 forecast for reported diluted EPS of $5.89 to $6.01.
• PMI also reaffirmed its adjusted diluted EPS forecast of $6.33 to $6.45.
• This adjusted EPS forecast represents a currency-neutral growth of 11% to 13% compared to 2023.
• The forecast includes adjustments for asset impairments, termination costs, and other items totaling $0.44 per share.
• An unfavorable currency impact of $0.34 per share was also factored into the forecast.
• PMI's smoke-free products accounted for approximately 38% of the company's total net revenues in the first half of 2024.
• As of June 30, 2024, PMI's smoke-free products were available in 90 markets, with an estimated 36.5 million adult users worldwide.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook with reaffirmed earnings forecasts and strong growth in smoke-free products, but also acknowledges risks and challenges.

Positives

• PMI is projecting a strong currency-neutral growth of 11% to 13% in adjusted diluted EPS for 2024.
• The company's smoke-free products are gaining traction, contributing 38% of total net revenues in the first half of 2024.
• PMI's smoke-free products are available in 90 markets, indicating a broad global reach.
• The company has a large user base of 36.5 million adults using smoke-free products.

Negatives

• The 2024 forecast includes a $0.34 per share negative impact from unfavorable currency exchange rates.
• The company faces risks related to regulatory restrictions, health concerns, and litigation.

Risks

• PMI faces risks from excise tax increases and discriminatory tax structures.
• Increasing marketing and regulatory restrictions could reduce competitiveness.
• Health concerns related to tobacco and nicotine use pose a risk.
• Litigation related to tobacco and intellectual property is a potential risk.
• Global economic, regulatory, and political developments can impact the business.
• The ongoing conflict in Ukraine presents a risk to PMI's operations.
• Changes in adult smoker behavior can affect sales.
• Counterfeiting, contraband, and cross-border purchases can lead to lost revenues.
• Unfavorable currency exchange rates and limitations on repatriating funds are risks.
• Adverse changes in corporate tax laws can impact profitability.
• The company faces risks related to the cost and availability of raw materials.
• The integrity of information systems and data privacy policies are also risks.
• The success of smoke-free products is not guaranteed and is subject to regulatory and market acceptance.

Future Outlook

PMI reaffirms its 2024 full-year earnings forecast and expects continued growth in its smoke-free product segment. The company aims to expand into wellness and healthcare areas through its Vectura Fertin Pharma business.

Management Comments

• PMI's Chief Executive Officer, Jacek Olczak, participated in a fireside chat session at the 2024 Barclays Global Consumer Staples Conference.

Industry Context

The announcement comes as the tobacco industry continues to shift towards smoke-free alternatives, with PMI positioning itself as a leader in this transition. The reaffirmation of the earnings forecast suggests confidence in the company's strategy and market position.

Comparison to Industry Standards

• PMI's focus on smoke-free products aligns with the broader industry trend of moving away from traditional cigarettes.
• Companies like British American Tobacco (BTI) and Altria (MO) are also investing in smoke-free alternatives, but PMI's 38% revenue contribution from these products in the first half of 2024 is a strong indicator of their progress.
• The 11-13% currency-neutral growth forecast is competitive within the consumer staples sector, but the specific performance of smoke-free products will be a key differentiator.
• PMI's investment of over $12.5 billion in smoke-free product development since 2008 is a significant commitment compared to some competitors.

Stakeholder Impact

• Shareholders can expect continued focus on growth and profitability.
• Employees will be involved in the development and commercialization of smoke-free products.
• Customers will have access to a wider range of smoke-free alternatives.
• Suppliers will be impacted by the shift in product focus.
• Creditors will be interested in the company's financial stability and growth prospects.

Next Steps

• PMI will continue to focus on expanding its smoke-free product portfolio.
• The company will monitor regulatory developments and market trends.
• PMI will continue to invest in research and development of smoke-free products.
• The company will work to mitigate risks related to currency fluctuations and other factors.

Key Dates

Keywords

Philip Morris International, PMI, Earnings Forecast, Smoke-Free Products, Adjusted EPS, Barclays Conference, Tobacco, Nicotine, IQOS, ZYN